Hurd v. Novartis Pharmaceuticals Corp., No. 20-CV-262 JAP/GBW (D. N.M. June 12, 2020)

Hurd v. Novartis Pharmaceuticals Corp., No. 20-CV-262 JAP/GBW (D. N.M. June 12, 2020)

Successfully defeated motion to dismiss filed by Defendant Novartis Pharmaceuticals Corp. in a case alleging that Novartis hid serious side effects of its blood cancer drug Tasigna, finding that the plaintiff was not required to preemptively refute Novartis’ affirmative defenses by alleging the exact date he was diagnosed with the drug’s side effects.

Justin R. Kaufman, PartnerRosalind Bienvenu, Partner